Paul Tudor Jones's TARS Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 9,541 shares of Tarsus Pharmaceuticals, Inc. (TARS) worth $600,511, representing 0.00% of the portfolio. First purchased in 2023-Q3, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in TARS, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 22,704 shares. Largest reduction occurred in Q4 2023, reducing 50,000 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Tarsus Pharmaceuticals (TARS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Tarsus Pharmaceuticals (TARS) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +9,541 | New Buy | 9,541 | $62.94 |
| Q1 2026 | -22,704 | Sold Out | 0 | $0.00 |
| Q4 2025 | +22,704 | New Buy | 22,704 | $81.88 |
| Q1 2025 | -13,880 | Sold Out | 0 | $0.00 |
| Q4 2024 | +13,880 | New Buy | 13,880 | $55.37 |
| Q2 2024 | -18,696 | Sold Out | 0 | $0.00 |
| Q1 2024 | +18,696 | New Buy | 18,696 | $36.35 |
| Q4 2023 | -50,000 | Sold Out | 0 | $0.00 |
| Q3 2023 | +50,000 | New Buy | 50,000 | $17.77 |
Paul Tudor Jones's Tarsus Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Tarsus Pharmaceuticals, Inc. (TARS) in Q3 2023, acquiring 50,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Tarsus Pharmaceuticals, Inc. (TARS) for 9 quarters since Q3 2023.
Paul Tudor Jones's largest addition to Tarsus Pharmaceuticals, Inc. (TARS) was in Q3 2023, adding 50,000 shares worth $888,500.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 9,541 shares of Tarsus Pharmaceuticals, Inc. (TARS), valued at approximately $600,511.
As of the Q2 2026 filing, Tarsus Pharmaceuticals, Inc. (TARS) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Tarsus Pharmaceuticals, Inc. (TARS) was 50,000 shares, as reported at the end of Q3 2023.